Ruben Mesa/LinkedIn
Aug 31, 2026, 14:28
Ruben Mesa: FDA Approves Ropeginterferon Alfa-2b for Essential Thrombocythemia
Ruben Mesa, President of Cancer National Service Line at Advocate Health, shared a post on LinkedIn:
“Honored to have been involved with (as PI of the Global Surpass ET trial) the now FDA approval of ROPEG INF a2b for patients with Essential Thrombocythemia.
This is the first approval in over 30 years for patients with this myeloid neoplasm MPN and helps decrease disease associated risks, symptoms, and modifies the underlying clone.”
Stay updated with Hemostasis Today.
-
Aug 31, 2026, 16:13Seema Dawood: Nucleated Red Blood Cells – What They Tell Us on a Peripheral Smear
-
Aug 31, 2026, 16:02Antonio Sorropago: Major Updates in Structural Heart Interventions
-
Aug 31, 2026, 15:44Andrea Boccatonda: Special Issue on Pulmonary Embolism and Venous Thromboembolism
-
Aug 31, 2026, 15:41Adrien Jossart: Acute Thrombotic Storm Following Single Heparin Bolus
-
Aug 31, 2026, 15:36Bernhard Gerber: Myocardial Platelet Activation Linked to Microvascular Obstruction After STEMI
-
Aug 31, 2026, 15:34Higher Fibrinogen γ′ Linked to Increased Risk of Recurrent Arterial Thrombosis – Journal of Thrombosis and Haemostasis
-
Aug 31, 2026, 15:21Ney Carter Borges: Anticoagulation Versus Antiplatelet Therapy After TAVI ESC 26
-
Aug 31, 2026, 15:13Nahid A. Qushmaq: MicroRNAs as Prognostic Biomarkers in Septic Patients
-
Aug 31, 2026, 14:32Mahir Khalil Ibrahim Jallo: Hot Topic From The ESC 2026 Munich